• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What Can Payers Do to Improve Biosimilar Uptake? Ryan Haumschild, PharmD, Weighs In

Video

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how payers can play an essential role in improving biosimilar adoption.

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how payers can play an essential role in improving biosimilar adoption at the Academy of Managed Care Pharmacy's annual meeting in Chicago, Illinois.

Transcript:

What more should payers being doing to improve biosimilar uptake and adoption?

Haumschild: Our payer colleagues are so essential to what we do and I think they understand the value of biosimilars. And I think the more you can leverage biosimilars as a preferred agent by the plan, you can reduce total cost of care, you can create some flexibility to health care providers to choose the best biosimilar for them, as long as they know a biosimilar is going to be the preferred treatment, and then continue to leverage real world evidence of biosimilar use so we can continue to expand that rollout across many different practice settings.

Related Videos
Mikkael Sekeres, MD
Jennifer Brown, MD, PhD
Ted Okon, MBA, of Community Oncology Alliance, during a Zoom video interview
Virginia Kaklamani, MD | image credit: uthscsa.edu
Ruben A. Mesa, MD, president and executive director of Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.